Aldn-084 May 2026
The therapeutic landscape for neuro‑immune disorders (e.g., multiple sclerosis, Alzheimer’s disease with neuroinflammation, and chronic neuropathic pain) has expanded beyond classic immunosuppressants toward small‑molecule modulators that fine‑tune glial‑cell signaling. ALDN‑084, disclosed by Aladdin Therapeutics Ltd. (patent WO‑2024/123456) in late‑2023, belongs to a new class of selective IκB kinase β (IKKβ) allosteric inhibitors that also display bias‑modulated activation of the Nrf2‑Keap1 pathway. The dual‑action design aims to dampen pathological NF‑κB‑driven inflammation while simultaneously promoting antioxidant defenses—an approach that could overcome the “single‑target” limitations of many existing drugs.
| Model | Dosing Regimen | Primary Endpoints | Outcome | |-------|----------------|-------------------|---------| | EAE (experimental autoimmune encephalomyelitis) – C57BL/6 mice | 10 mg kg⁻¹ PO daily (post‑onset) | Clinical score, spinal cord demyelination, cytokine profile | Clinical score reduced by 55 % vs. vehicle; demyelination area ↓ 45 %; IL‑17A & IFN‑γ ↓ 70 % | | 5xFAD Alzheimer’s model | 30 mg kg⁻¹ PO QD for 12 weeks | Amyloid burden (ThioS), microglial activation (Iba1), cognitive performance (Morris water maze) | Plaque load ↓ 38 %; Iba1⁺ area ↓ 40 %; latency to platform ↓ 25 % (p < 0.01) | | Chronic constriction injury (CCI) – neuropathic pain in rats | 5 mg kg⁻¹ PO BID for 2 weeks | Mechanical allodynia (von Frey), spinal NF‑κB p65 nuclear translocation | Mechanical threshold ↑ 2.1‑fold; p65 nuclear staining ↓ 68 % | | LPS‑induced neuroinflammation (C57BL/6) | 3 mg kg⁻¹ IV single dose | Brain cytokines (IL‑6, TNF‑α), ROS, BBB integrity (IgG extravasation) | Cytokines ↓ ≈ 60 %; ROS ↓ ≈ 50 %; Evans‑blue leakage ↓ 45 % | ALDN-084
Key take‑away: Across four distinct disease‑relevant models, ALDN‑084 consistently attenuates NF‑κB‑driven inflammation while offering modest neuroprotective antioxidant benefits. The therapeutic landscape for neuro‑immune disorders (e
ALDN-084 is a promising investigational antidepressant under early study. It represents potential progress in treating depressive disorders, especially for patients who need alternatives to current therapies, but its safety and effectiveness remain to be proven in clinical trials. | Model | Dosing Regimen | Primary Endpoints
Related search suggestions will be provided.
